Clinical trials: Uremic Toxin
End Stage Renal Failure on Dialysis
Effect of Prebiotics and/or Probiotics on Uremic Toxins and Inflammation Markers in Peritoneal Dialysis Patients
End-stage renal disease (ESRD) is a world public health problem, with high morbidity and mortality. Cardiovascular disease is the main cause of mortality in ESRD; uremic toxin retention and inflammation are considered…
- Trial name
- NCT03770611
- Testing
- Probiotic, Prebiotic, Symbiotic
- Where
- Mexico
- Volunteers
- 112 people
- Sponsor
- Unidad de Investigacion Medica en Enfermedades Renales
Hemolytic Uremic Syndrome of Childhood
Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHU
The investigators aim to perform the first controlled randomized prospective study using ECZ in pediatric STEC-HUS. This is of great interest as there is still no efficient specific therapy in that potentially devastating…
- Trial name
- ECULISHU (NCT02205541)
- Testing
- Eculizumab
- Where
- 18 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Toulouse
End Stage Renal Disease, Chronic Kidney Failure
Comparison of Conventional Dialysis and the Allient System
The purpose of the study to determine whether the level of inflammation may be decreased, the lifespan of red blood cells increased and the clearance of waste products in the blood improved through the use of the Allient System…
- Trial name
- NCT00788905
- Testing
- Allient System
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Renal Research Institute
CKD, PAD - Peripheral Arterial Disease
Oral Absorbent and Probiotics in CKD Patients With PAD on Gut Microbiota, IncRNA, Metabolome, and Vascular Function
Taiwan has more chronic kidney disease (CKD) per capita than anywhere in the world, leading to the highest expense of National Health Insurance.
- Trial name
- NCT04792320
- Testing
- Active bamboo charcoal, probiotics
- Where
- Taiwan
- Volunteers
- 180 people
- Sponsor
- National Taiwan University Hospital
End Stage Renal Disease (ESRD)
Comparison of the Removal of Uremic Toxins With Medium Cut-off and Super High-flux Vitamin E-coated Dialyzers
End-stage renal disease (ESRD) induces an accumulation of uremic toxins responsible for increased morbidity and mortality. These toxins cover a wide range of molecules, classified according to their molecular weight as small-size…
- Trial name
- E-FLUX (NCT05610683)
- Testing
- Hemodialysis sessions using SHFVE dialyzer (VieX™) or the MCO (Theranova 500™) dialyzer
- Where
- France
- Volunteers
- 41 people
- Sponsor
- Poitiers University Hospital
End Stage Renal Disease on Dialysis
Efficacy of pHA130 Hemoadsorption for 4 Hours (p4H Study)
This is an open-label, randomized, crossover study to evaluate the efficacy of extending the duration of hemoadsorption (HA) combined with hemodialysis (HD) from 2 hours to 4 hours for clearing protein-bound uremic toxins, such…
- Trial name
- NCT07111260
- Testing
- pHA130 Hemoadsorption + High-Flux Hemodialysis
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Peking University People's Hospital
Bloody Diarrhea, STEC, Unspecified
Phase 2/3 Study to Evaluate PK, Safety & Efficacy of INM004 in STEC Positive Pediatric Patients for Prevention of HUS
The investigational medicinal product (IMP), INM004, proposes to neutralize the toxin in the bloodstream to prevent the interaction of the Stx with the specific receptor, by means of a polyclonal antibody to be administered upon…
- Conditions
- Bloody Diarrhea, STEC, Unspecified, Hemolytic-Uremic Syndrome, Pediatric Kidney Disease
- Trial name
- NCT04132375
- Testing
- INM004
- Where
- 7 sites in Argentina
- Volunteers
- 11 people
- Sponsor
- Inmunova S.A.
Acute Kidney Injury, Uremic; Toxemia
Prognostic Role of the Uremic Toxin Indoxyl Sulfate on Vascular and Cardiac Functions During Acute Kidney Injury
Acute kidney injury (AKI) is a frequent disease in conventional hospital departments and in intensive care units. It's associated with a high risk to develop chronic kidney disease (CKD), even after a single small AKI episode.
- Conditions
- Acute Kidney Injury, Uremic; Toxemia, Vascular Dysfunction, Cardiac Dysfunction
- Trial name
- VASC-AKI (NCT05659589)
- Testing
- blood sample
- Where
- France
- Volunteers
- 105 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Acute Renal Failure, Iatrogenic Effect
Detection of Acute Renal Failure Using Hospital Coding Data
AKI is a rapid and usually reversible impairment of kidney function that is life-threatening in the short term well described by the "Kidney Disease: Improving Global Outcomes - KDIGO" classification of 2012.
- Conditions
- Acute Renal Failure, Iatrogenic Effect, Uremic Toxin
- Trial name
- IRA-PMSI (NCT04923750)
- Where
- France
- Volunteers
- 498 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis
National Registry of Rare Kidney Diseases
The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research.
- Conditions
- Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis, AHL Amyloidosis, AL Amyloidosis
- Trial name
- RaDaR (NCT06065852)
- Where
- United Kingdom
- Volunteers
- 35,000 people
- Sponsor
- UK Kidney Association
End Stage Renal Disease on Dialysis
Coated Aldehyde Oxystarch for Protein-Bound Uremic Toxin Reduction in End-Stage Renal Disease
The goal of this clinical trial is to learn if Coated Aldehyde Oxystarch (Xiqing) works to reduce protein-bound uremic toxins (PBUTs) in adults with end-stage renal disease (ESRD).
- Trial name
- NCT07653711
- Testing
- Coated Aldehyde Oxystarch
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University People's Hospital
End Stage Renal Disease, Chronic Hemolysis
Development of an Innovative Hemodialysis Method to Improve Dialytic Clearance of Protein-bound Uremic Toxins
Current hemodialysis techniques fail to efficiently remove protein-bound uremic toxins (such as p-cresyl sulfate (p-CS) or indoxyl sulfate (IS)) due to their strong binding to serum albumin.
- Trial name
- CLEARTOX (NCT06595680)
- Testing
- Medialipide 20% perfusion, NaCl 0,9%, Blood sample
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Hospices Civils de Lyon
Chronic Kidney Diseases
Uremic Toxins and Outcomes in Chronic Kidney Disease
The aim of this cohort study is: To investigate the etiology and epidemiology of comorbidities in CKD; To find out risk factors associated with the mortality of CKD; To find out uremic toxins which are related to the mortality…
- Trial name
- NCT03711617
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Chronic Kidney Diseases
Impact of Dapagliflozin on Intestinal Microbiota Composition and on the Metabolites Derived From the Intestinal Microbiota in Non-diabetic Chronic Renal Failure Patients
Chronic kidney disease (CKD) is a common disease affecting 10-12% of the adult population and characterize with high-risk cardiovascular morbidity and mortality with progression of CKD.
- Trial name
- DAPA-GUT (NCT05965440)
- Testing
- impact of Dapagliflozin on Intestinal Microbiota on chronic renal failure patients
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Hemodialysis
NATURE 3.2_New Approach for the Reduction of REnal Uremic Toxins
The objective of the pilot study is to validate a combined approach based on the use of an innovative symbiotic and an innovative dialysis cartridge in patients on hemodialysis (HD).
- Trial name
- NATURE32 (NCT03946176)
- Testing
- Symbiotic, DVB cartridge
- Where
- Italy
- Volunteers
- 16 people
- Sponsor
- Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
End Stage Kidney Disease
Protein-bound Uremic Retention Solutes and Long Nocturnal Hemodialysis: a Longitudinal Analysis
Study on intradialytic kinetics of protein-bound uremic retention solutes during long nocturnal hemodialysis
- Trial name
- NCT00417339
- Testing
- hemodialysis
- Where
- 4 sites in Australia, Belgium
- Volunteers
- 38 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Uremic; Toxemia
A Comparison of Protein-bound and Large Molecular Weight Uremic Toxin Removals With Novel Super High-flux Dialyzer Between Hemodialysis and High Volume Online HDF Modalities
The goal of this prospective, randomized, crossover study is to study about using super high-flux dialyzer in the chronic hemodialysis patients.
- Trial name
- NCT06567483
- Testing
- ELISIO21HX
- Where
- Thailand
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Chulalongkorn University
ESRD (End-Stage Renal Disease), Maintenance Hemodialysis
Efficacy of pHA130 Hemoadsorption on Protein-Bound Uremic Toxins and Quality of Life in Kidney Failure
Patients on maintenance hemodialysis (MHD) face a high risk of cardiovascular mortality and reduced quality of life. Conventional high-flux hemodialysis (HD) is the standard of care but has limited efficacy in clearing…
- Trial name
- PHOENIX (NCT07656168)
- Testing
- pHA130 Hemoadsorption Cartridge, High-flux Hemodialyzer
- Where
- China
- Volunteers
- 100 people
- Sponsor
- China-Japan Friendship Hospital
Chronic Kidney Disease (Stages 4 and 5), Peritoneal Dialysis (PD)
Probiotic and Prebiotic Supplementation in Peritoneal Dialysis Patients
The goal of this clinical trial is to learn if synbiotics work to lower inflammation in adults with chronic kidney disease who are on peritoneal dialysis.
- Trial name
- NCT07694791
- Testing
- Synbiotic
- Where
- Mexico
- Volunteers
- 60 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Renal Failure, Multi Organ Failure
Uremic Toxins in the Intensive Care Unit (ICU): Patients With Sepsis
Study of the kinetics of uremic toxins in the ICU patients with acute renal failure, in order to optimize the dialysis dose: patients with sepsis/multi-organ failure.
- Trial name
- NCT00752245
- Testing
- Dialysis during 4 hours, Dialysis during 6 hours, Dialysis during 8 hours
- Where
- Belgium
- Sponsor
- University Hospital, Ghent